Clovis inks deal with Bristol-Myers Squibb
BOULDER — Clovis Oncology Inc. (Nasdaq: CLVS) has entered into a clinical agreement with Bristol-Myers Squibb (NYSE: BMY).
The two companies will test the combination of Clovis’ Rubraca drug with Bristol-Myer Squibb’s immunotherapy Opdivo across multiple tumor types.
The Phase 3 studies will be conducted in advanced ovarian cancer and advanced triple-negative breast cancer. The partnership will also include a Phase 2 clinical trial in metastatic prostate cancer.
SPONSORED CONTENT
The many benefits of simple, coordinated healthcare
Kaiser Permanente combines health care and coverage in one connected system to maximize employee health and minimize employer costs.
Boulder-based Clovis will be in charge of running the ovarian cancer tests while Bristol-Myers operates the prostate and breast cancer studies.
All three tests should be started before the end of the year.
Clovis’ stock fell over the weekend, down from $98 when the market closed on Friday to $92.40 per share when the market opened on Monday. Stock has steadily declined since then and was at $85.20 at time of publication.